PHK
CBAY

Point72 Hong Kong’s Cymabay Therapeutics CBAY Stock Holding History

Point72 Hong Kong’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,517
Closed -$8K – 2518
2022
Q1 		$8K Buy
+2,517
New +$7.92K ﹤0.01% 1637
2021
Q4 		– Sell
-610
Closed -$2K – 2522
2021
Q3 		$2K Sell
610
-1,016
-62% -$4K ﹤0.01% 1888
2021
Q2 		$7K Buy
+1,626
New +$7.21K ﹤0.01% 1777
2021
Q1 		– Sell
-9,868
Closed -$57K – 2305
2020
Q4 		$57K Buy
+9,868
New +$74.7K ﹤0.01% 1196
2020
Q3 		– Sell
-10,402
Closed -$36K – 1612
2020
Q2 		$36K Buy
10,402
+9,513
+1,070% +$27.5K ﹤0.01% 792
2020
Q1 		$1K Sell
889
-1,472
-62% -$2.47K ﹤0.01% 885
2019
Q4 		$5K Buy
2,361
+2,093
+781% +$7.86K ﹤0.01% 1044
2019
Q3 		$1K Buy
+268
New +$1.62K ﹤0.01% 929
2018
Q3 		– Sell
-3,835
Closed -$51K – 1245
2018
Q2 		$51K Buy
+3,835
New +$48K 0.02% 426

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Point72 Hong Kong's CBAY Position: Q2 2022 in Review

Point72 Hong Kong sold out of Cymabay Therapeutics (CBAY) in Q2 2022, closing a stake of 2,517 shares — an estimated $8K sold.

Point72 Hong Kong first reported a position in CBAY in Q2 2018 and held it in 9 quarters. The position peaked at $57K in Q4 2020. 106 funds tracked by Wall St. Rank hold CBAY as of Q2 2022.

  • Point72 Hong Kong reported no remaining Cymabay Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 2,517 Cymabay Therapeutics shares in Q2 2022, an estimated $8K.
  • Point72 Hong Kong first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 9 quarters.
  • Point72 Hong Kong's Cymabay Therapeutics position peaked at $57K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2022.

Based on Point72 Hong Kong's 13F filing for Q2 2022, filed 15 Aug 2022.